Based on previous studies that have shown a protective role of VWF in the initiation of metastatic foci, a phase II dose-escalation clinical trial (NCT01606072) investigated the provision of high-dose perioperative desmopressin (dDAVP) to reduce metastasis in breast cancer patients [95]. The gene discussed is VWF; the disease is breast carcinoma.